Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?
This week: UK set to make drug approvals ‘faster and nimbler’, which could help MDMA-assisted therapy; ketamine clinics close, which could damage future PAT infrastructure; psychedelics at SXSW; and lots more…
Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?
This week: we look at changes to COMPASS’ Phase 3 program; the Stamets Stack’s patent; and, we evaluate Zuranolone as a potential comp for psychedelic therapies. Plus lots more…
Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?
This week, we look at how the European Medicines Agency might be warming up to the idea of psychedelic therapies, how MDMA could be approved in the UK shortly after any FDA approval via a new pathway; and what’s next for at-home ketamine therapy. Plus lots more…
Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A
A look at Australia’s rescheduling of MDMA and Psilocybin; Small Pharma’s Phase 2a DMT results; Journey Clinical’s Series A round; and lots more…
Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’
This week: we briefly look at four new psychedelic policy reform bills from across the U.S.; the World Health Organisation gives 5-MeO-DMT a generic name; and more…
Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications
This week: PCN-101 results disappoint; MDMA for PTSD appears to have succeeded in second Phase 3 study; a Bill introduced in New York would legalize a number of psychedelics; Oregon begins accepting applications for psilocybin-related licences; and much more…